Bloomia Holdings, Inc. (TULP) Announces Extension of Rights Offering Back to the Newsroom Bloomia Holdings, Inc. (TULP) Announces Extension of Rights Offering MINNEAPOLIS, MN / ACCESS Newswire/ March 27, 2026 / Bloomia Holdings, Inc. (the "Company") today announced that it has extended the subscription period for its previously announced rights offering. The subscription period for the rights offering, which was originally scheduled to expire on March 27, 2026, has been ext ...

Core Viewpoint - Neuberger High Yield Strategies Fund Inc. has announced the issuance of transferable rights to its common stockholders, allowing them to subscribe for additional shares at a discount to market price, aimed at increasing the Fund's assets to capitalize on investment opportunities [1][2]. Fund Details - The Fund's investment objective is to seek high total return, which includes both income and capital appreciation, by investing at least 80% of its total assets in high yield debt securities [8][9]. - Neuberger Berman Investment Advisers LLC, the Fund's investment adviser, believes it is an opportune time to raise additional assets due to favorable market conditions [3]. Offer Structure - Record Date Stockholders will receive one Right for each share owned, allowing them to purchase one new share for every three Rights held, with a subscription price set at 95% of the average market price on the expiration date [5]. - The Offer is expected to enhance long-term returns, provide stockholders the opportunity to buy shares below market price, and improve the total expense ratio by spreading fixed costs over a larger asset base [4]. Distribution Information - The Fund has declared regular monthly distributions for March and April 2026, which will not apply to shares issued under the Offer, but shares purchased through the Offer will be eligible for the May distribution [3]. Rights Trading - The Rights will be transferable and are expected to be traded on the NYSE American under the symbol "NHS RT" until April 14, 2026, one day before the Offer's expiration [5].

Core Viewpoint - AIM ImmunoTech Inc. is conducting a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, which is a significant global health issue [1][8]. Rights Offering Details - Each subscription right allows holders to purchase one unit, consisting of one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants, at a subscription price of $1,000 per unit [2]. - The Preferred Stock is convertible into 1,000 shares of Common Stock at the holder's option, with a conversion price of $1.00 per share [2]. - Each Warrant can be exercised for one share of Common Stock at an exercise price of $1.00 per share, valid for five years from issuance [2]. Participation Requirements - Record holders wishing to participate must submit a completed rights certificate and payment to the Subscription Agent by 5:00 p.m. Eastern Time on March 3, 2026 [3]. - Subscription rights are non-transferable and cannot be revoked once exercised [4]. Management and Regulatory Aspects - Maxim Group LLC has been appointed as the dealer-manager for the Rights Offering [5]. - The offering is conducted under a registration statement declared effective by the SEC on February 10, 2026, and is available through the SEC's website [6]. Company Overview - AIM ImmunoTech Inc. focuses on immuno-pharmaceutical research and development, particularly for Ampligen®, which is a dsRNA and selective TLR3 agonist with demonstrated activity in clinical trials [8][9].

Core Viewpoint - Empire Petroleum Corporation has modified the terms of its subscription rights offering, allowing shareholders to purchase additional shares of Common Stock at a set price, aiming to raise approximately $10 million through this initiative [1]. Group 1: Rights Offering Details - The subscription rights offering allows holders of Common Stock to purchase 0.095 shares at a price of $2.99 per whole share, requiring a minimum of 11 shares to receive subscription rights [1]. - The expiration date for the Rights Offering has been extended to March 18, 2026, with the possibility of further extensions or early termination [2]. - Holders of subscription rights will receive a prospectus and related materials to guide them through the process of exercising their rights [4]. Group 2: Shareholder Participation - Energy Evolution Master Fund, Ltd., the largest shareholder, intends to fully participate in the Rights Offering and exercise over-subscription rights for any remaining shares [3]. - Phil E. Mulacek, the Chairman of the Board, has also expressed intent to participate in the offering [3]. Group 3: Company Overview - Empire Petroleum Corporation is a publicly traded oil and gas company with assets in New Mexico, North Dakota, Montana, Texas, and Louisiana, focusing on organic growth and strategic acquisitions [7].

Financial Data and Key Metrics Changes - Distributable Earnings for Q4 2025 were reported at $4.6 million, or $0.28 per share, with an adjusted figure of $0.31 per share when accounting for the rights offering dilution [4][16] - The company raised $61.5 million in net proceeds from a rights offering, increasing investment capacity by over $200 million [4][5] - For the full year of 2025, distributable earnings were $1.21 per share, with a run rate annual dividend of $1.12 per share, representing a 93% payout ratio [16][19] Business Line Data and Key Metrics Changes - The loan portfolio increased by $83 million year-over-year, reaching total commitments of $724.5 million across 24 floating-rate first mortgage loans [8] - The weighted average all-in yield was reported at 7.92%, with a weighted average risk rating improving to 2.8 [8] - The company invested in three new loans totaling $101.3 million during Q4 2025, including loans secured by student housing, a hotel, and an industrial property [5][7] Market Data and Key Metrics Changes - Market conditions improved in Q4 2025, with two additional 25 basis point rate cuts, bringing the target Fed funds rate to 350-375 basis points [11] - Office transaction volume increased by 25% year-over-year, indicating a recovery in the market [12] - Demand for short-term floating rate bridge loans remains strong, with a broad range of transactions being evaluated [13][14] Company Strategy and Development Direction - The company aims to capitalize on middle-market lending opportunities with enhanced liquidity following the rights offering [9] - There is a focus on deploying capital selectively into attractive opportunities across various property types and geographies [13] - The strategy remains centered on senior secured positions, avoiding riskier junior tranches for the time being [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about transaction activity continuing to increase in 2026, driven by improving market conditions and increased financing activity [12][13] - The company expects first quarter distributable earnings to be in the range of $0.22 to $0.24 per share, with a temporary drag on earnings due to the rights offering [18] - The expectation is to reach close to $1 billion in total loan portfolio size by year-end 2026, with quarterly new originations targeted at $200 million [34] Other Important Information - The company ended Q4 2025 with $123 million in cash and extended the maturities of two secured financing facilities, increasing capacity to $377 million [19][20] - The CECL reserve remains modest at 130 basis points of total loan commitments, indicating a conservative risk profile [19] Q&A Session Summary Question: How is the company finding pockets of inefficiency in the current competitive environment? - Management noted that while multifamily contributes significantly to activity, they are focusing on sectors like storage, industrial, and medical office for better risk-adjusted returns [24][25] Question: Are there opportunities outside of the first lien space being evaluated? - Management confirmed that the focus remains on senior secured positions, with no current plans to explore mezzanine or preferred equity [26] Question: Does the distributable EPS guidance assume full deployment of the rights offering capital? - Management clarified that the guidance does not assume full deployment by the end of Q1, but expects earnings to recover by year-end [29] Question: Is the current dividend secure through the end of 2026? - Management affirmed commitment to the $0.28 per quarter dividend, despite temporary earnings drag from the rights offering [33] Question: What is the expected portfolio growth following the rights offering? - Management anticipates reaching close to $1 billion in total loan portfolio size by year-end, with significant new originations expected in the coming quarters [34]

Core Viewpoint - The company successfully completed a $61.5 million net rights offering, enhancing its investment capacity by over $200 million to take advantage of a recovering transaction environment [1] Financial Performance - Achieved a fully performing loan portfolio with zero nonaccruals, supported by a weighted average risk rating improvement to 2.8 and a conservative 66% loan-to-value (LTV) at origination [1] - Observed a 25% year-over-year increase in office transaction volume, indicating stabilizing pricing and improved debt capital availability for the asset class [1] Capital Deployment - Accelerated capital deployment with $101.3 million in new commitments during Q4, targeting diverse sectors including student housing, hospitality, and industrial properties [1] - Benefited from interest rate floors on all but one loan, providing $0.01 of earnings protection in Q4 and serving as a hedge against a declining SOFR environment [1] Underwriting Strategy - Maintained a disciplined underwriting approach by avoiding the 'race to the bottom' in multifamily yields, instead finding outsized risk-adjusted returns in medical office and self-storage [1] Shareholder Alignment - Strengthened alignment with shareholders as the manager increased its ownership stake to over 20% following the rights offering participation [1]

Shareholders Received Total Return of 27.32% in 2025 Reaffirms 10% Distribution Policy of $0.60 Per Share Annually Announces Rights Offering for Common Shares RYE, N.Y., Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of The Gabelli Equity Trust (NYSE: GAB) (the “Fund”) reaffirmed the Fund’s distribution policy of paying $0.60 per share annually, and has approved a transferable rights offering which will allow the Fund’s record date common shareholders to acquire additional shares of common stock ( ...

As filed with the Securities and Exchange Commission on February 13, 2026 Registration No. 333-292897 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 AMENDMENT NO. 1 FORMS-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BLOOMIA HOLDINGS,INC. (Exact name of registrant as specified in its charter) Delaware 0100 41-1656308 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code (I.R.S. Employer Identification Number) Num ...

As filed with the Securities and Exchange Commission on February 13, 2026 Registration No. 333-292897 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 AMENDMENT NO. 1 FORMS-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BLOOMIA HOLDINGS,INC. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification Number) Number) 5000 West 36th Street, Suite 220, Minneapolis, Minnesota 55416 Delaware 0100 41-1656308 (State or other jurisdiction of incorporatio ...

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen®, aimed at treating late-stage pancreatic cancer, with an expected gross proceeds of $12 million if fully subscribed [2][5]. Group 1: Rights Offering Details - The rights offering allows holders of the company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [3][4]. - Each unit consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock, with the preferred stock convertible into 833 shares of common stock at a conversion price of $1.20 per share [4]. - The subscription rights are non-transferable and must be exercised by 5:00 p.m. Eastern Time on February 27, 2026, unless extended by the company [6]. Group 2: Financial Implications - If the rights offering is fully subscribed, the company anticipates receiving aggregate gross proceeds of $12 million [5]. - Holders who fully exercise their basic subscription rights will have the opportunity to subscribe for additional units that remain unsubscribed due to unexercised basic subscription rights [5]. Group 3: Company Background - AIM ImmunoTech Inc. is focused on the research and development of Ampligen® (rintatolimod), which is a highly selective TLR3 agonist immuno-modulator showing promise in treating late-stage pancreatic cancer [12].